Literature DB >> 17476478

[Pharmacotherapeutic aspects of femoral head necrosis].

I H Tarner1, R Dinser, U Müller-Ladner.   

Abstract

Avascular necrosis (AVN) of the hip is one of the unsolved problems in orthopedics, especially with regard to drug therapy. Only a few studies exist using a long-term approach with vasodilating agents such as prostaglandins, anticoagulants, hormones, as well as lipid lowering and bone protective drugs such as bisphosphonates. However, using these medications several studies have demonstrated a significant reduction in pain, in the destruction of the femoral head as well as in overall disability. This resulted in a reduced need for joint replacement in patients with AVN and to a substantial improvement in quality of life. Of note, drug therapy should be initiated in the early phases of AVN as later stages appear to be less responsive to medication.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17476478     DOI: 10.1007/s00132-007-1084-5

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  23 in total

1.  Hyperbaric oxygen therapy as a treatment for stage-I avascular necrosis of the femoral head.

Authors:  H J Kim
Journal:  J Bone Joint Surg Br       Date:  2004-01

2.  Efficacy of alendronate in the treatment of avascular necrosis of the hip.

Authors:  M M Desai; S Sonone; V Bhasme
Journal:  Rheumatology (Oxford)       Date:  2005-06-21       Impact factor: 7.580

3.  The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study.

Authors:  Kuo-An Lai; Wun-Jer Shen; Chyun-Yu Yang; Chung-Jung Shao; Jui-Ting Hsu; Ruey-Mo Lin
Journal:  J Bone Joint Surg Am       Date:  2005-10       Impact factor: 5.284

4.  The fate of nontraumatic avascular necrosis of the femoral head. A radiologic classification to formulate prognosis.

Authors:  K Ohzono; M Saito; N Sugano; K Takaoka; K Ono
Journal:  Clin Orthop Relat Res       Date:  1992-04       Impact factor: 4.176

5.  Enoxaparin prevents progression of stages I and II osteonecrosis of the hip.

Authors:  Charles J Glueck; Richard A Freiberg; Luann Sieve; Ping Wang
Journal:  Clin Orthop Relat Res       Date:  2005-06       Impact factor: 4.176

6.  Statin therapy decreases the risk of osteonecrosis in patients receiving steroids.

Authors:  J W Pritchett
Journal:  Clin Orthop Relat Res       Date:  2001-05       Impact factor: 4.176

Review 7.  Nontraumatic osteonecrosis of the femoral head: ten years later.

Authors:  Michael A Mont; Lynne C Jones; David S Hungerford
Journal:  J Bone Joint Surg Am       Date:  2006-05       Impact factor: 5.284

8.  Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study.

Authors:  S Agarwala; D Jain; V R Joshi; A Sule
Journal:  Rheumatology (Oxford)       Date:  2004-11-30       Impact factor: 7.580

9.  Long-term observation of avascular necrosis of the femoral head in systemic lupus erythematosus: an MRI study.

Authors:  T Yoshida; Y Kanayama; M Okamura; N Negoro; T Inoue; J Yoshikawa
Journal:  Clin Exp Rheumatol       Date:  2002 Jul-Aug       Impact factor: 4.473

10.  Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein(a), and therapy with Stanozolol.

Authors:  C J Glueck; R Freiberg; H I Glueck; T Tracy; D Stroop; Y Wang
Journal:  Am J Hematol       Date:  1995-04       Impact factor: 10.047

View more
  2 in total

Review 1.  [Conservative treatment of atraumatic femoral head necrosis].

Authors:  U Maus; J Flechtenmacher; K M Peters
Journal:  Orthopade       Date:  2018-09       Impact factor: 1.087

Review 2.  [Bone marrow edema and atraumatic necrosis of the femoral head : Therapy].

Authors:  J Beckmann; A Roth; C Niethard; F Mauch; R Best; U Maus
Journal:  Orthopade       Date:  2015-09       Impact factor: 1.087

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.